The American journal of managed careHumansUnited StatesImmunotherapyAdoptiveInsurance
It's time to reimagine reimbursement for CAR T-cell therapy.
Anna Sureda, Meagan O'Neill, Brian O'Rourke
Published: 202510.37765/ajmc.2025.89878
Abstract
Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions.